RGD Reference Report - Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.

Authors: Takahashi, T  Yano, M  Minami, J  Haraguchi, T  Koga, N  Higashi, K  Kobori, S 
Citation: Takahashi T, etal., Diabetes Res Clin Pract. 2002 Nov;58(2):123-9.
RGD ID: 7257687
Pubmed: PMID:12213354   (View Abstract at PubMed)

We have recently demonstrated that serotonin (5-HT) increases the production of type 4 collagen by cultured human mesangial cells. Here we examined the clinical effects of a 5-HT(A2) receptor antagonist whether it would prevent the development or progression of diabetic nephropathy. We compared the levels of 5-hydroxyindole-3-acetic acid (5-HIAA), the major metabolite of 5-HT, in 24-h urine samples of patients with type 2 diabetes (n=110) and normal subjects (n=40). We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group. Urinary 5-HIAA in diabetic patients was significantly higher (3.44+/-1.43 mg/day) than in normal subjects (1.62+/-0.50 mg/day, P<0.001), and correlated significantly with hemoglobin A1c (r=0.56, P<0.001) and with fasting blood glucose (r=0.37, P<0.001). Sarpogrelate significantly reduced urinary albumin excretion level within 3 months of commencement of treatment (24.3+/-8.58 mg/g Cr, P<0.05), which was persistently seen during the treatment, while no such change was noted in the control group (32.2+/-13.4 mg/g Cr). Our study indicate that high levels of 5-HT in type 2 diabetics may be one of the underlying mechanisms of diabetic nephropathy, and that treatment with 5-HT(A2) receptor antagonists may reduce or inhibit the development of nephropathy.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
HTR2AHumanDiabetic Nephropathies  IMP associated with Diabetes Mellitus Type 2 and RGD 
Htr2aRatDiabetic Nephropathies  ISOHTR2A (Homo sapiens)associated with Diabetes Mellitus Type 2 and RGD 
Htr2aMouseDiabetic Nephropathies  ISOHTR2A (Homo sapiens)associated with Diabetes Mellitus Type 2 and RGD 

Objects Annotated

Genes (Rattus norvegicus)
Htr2a  (5-hydroxytryptamine receptor 2A)

Genes (Mus musculus)
Htr2a  (5-hydroxytryptamine (serotonin) receptor 2A)

Genes (Homo sapiens)
HTR2A  (5-hydroxytryptamine receptor 2A)


Additional Information